Journal
CANCER RESEARCH
Volume 81, Issue 1, Pages 27-34Publisher
AMER ASSOC CANCER RESEARCH
DOI: 10.1158/0008-5472.CAN-20-2339
Keywords
-
Categories
Funding
- Special Research Fund of Ghent University (BOF)
- Stand Up to Cancer (Kom Op Tegen Kanker)
- Research Foundation-Flanders (FWO)
Ask authors/readers for more resources
Tumor-derived secretory factors influence splenic hematopoietic and stromal cells to promote tumor metastasis. While animal models provide valuable insights, translating these findings to clinical practice poses specific challenges.
Tumor-derived secretory factors orchestrate splenic hematopoietic and stromal cells to fuel metastasis. The spleen acts as a reservoir site for hematopoietic stem and progenitor cells, which are rapidly exploited as myeloid-derived suppressor cells at the cost of tumor-reactive lymphoid cells. Splenic erythroid progenitor cells and mesenchymal stromal cells contribute directly and indirectly to both tumor immune escape and the metastatic cascade. Animal models provide valuable mechanistic insights, but their translation to a clinical setting highlights specific challenges and open issues. In this review, we envision the exploitation of the spleen as a source for novel biomarkers and therapeutic approaches.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available